Current Edition


Trial setback casts doubt on a biotech’s respiratory virus drug

Dive Brief: Enanta Pharmaceuticals’ pill to combat respiratory syncytial virus didn’t work in low-risk patients, with the company reporting Wednesday the antiviral did not significantly …

Continue Reading →

Lilly’s closely watched diabetes drug scores in obesity trial

Dive Brief: Eli Lilly’s experimental diabetes shot tirzepatide helped obese people who have an underlying medical condition lose more than 15% of their body weight …

Continue Reading →

Kodiak crashes on negative trial results for would-be Eylea competitor

Dive Brief: Shares in Kodiak Sciences plummeted by 80% in Wednesday morning trading, erasing about $2 billion in market value, after the biotech company’s experimental …

Continue Reading →

Pressure rises as Gilead awaits important study results for top cancer drug

Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast …

Continue Reading →

Cannabics Pharma clinches clinical trial on Cannabics SR 5mg for CACS

The company is awaiting for the results and expect them to further clarify an important part of their mission in integrating cannabinoid-based therapies into the …

Continue Reading →